Compounds > 23-epi-26-deoxyactein
Page last updated: 2024-11-13

23-epi-26-deoxyactein

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

23-epi-26-deoxyactein: 23-epi-26-deoxyactein was previously designated as 27-deoxyactein; from the roots/rhizomes of Cimicifuga racemosa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21668683
CHEBI ID70243
SCHEMBL ID563205
MeSH IDM0427979

Synonyms (23)

Synonym
23-epi-26-deoxyactein
gcmgjwlogksugx-wuhyqcrdsa-
CHEBI:70243
SCHEMBL563205
beta-d-xylopyranoside, (3beta,12beta,16beta,23s,24r,25r)-12-(acetyloxy)-16,23:23,26: 24,25-triepoxy-9,19-cyclolanostan-3-yl
unii-2a97xp2v7i
23-epi-26-deoxy-actein
23-epi-26-deoxyactein [usp-rs]
.beta.-d-xylopyranoside, (3.beta.,12.beta.,16.beta.,23s,24r,25r)-12-(acetyloxy)-16,23:23,26: 24,25-triepoxy-9,19-cyclolanostan-3-yl
501938-01-8
2A97XP2V7I ,
23-epi-26-deoxyactein (constituent of black cohosh) [dsc]
DTXSID0033388 ,
Q27138581
(1r,2r,2a'r,4's,5r,6a'r,7a'r,9'r,9a'r,9b'r,10'r,13a's,14a's,14b's)-3',3',5,9a',10',14a'-hexamethyl-4'-(((2s,3r,4s,5r)-3,4,5-trihydroxytetrahydro-2h-pyran-2-yl)oxy)octadecahydro-3,6-dioxaspiro[bicyclo[3.1.0]hexane-2,12'-cyclopropa[1',8a']naphtho[2',1':4,5]
[(1r,1'r,3'r,4r,4'r,5r,5'r,6'r,10's,12's,13's,16'r,18's,21'r)-1,4',6',12',17',17'-hexamethyl-18'-[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxyspiro[3,6-dioxabicyclo[3.1.0]hexane-4,8'-9-oxahexacyclo[11.9.0.01,21.04,12.05,10.016,21]docosane]-3'-yl] acetate
MS-31019
CS-0179273
HY-139058
dtxcid60820004
23-epi-26-deoxyactein (constituent of black cohosh)
23-epi-26-deoxyactein (usp-rs)
PD195634

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic analyses of 23-epi-26-deoxyactein in sera indicated that the maximum concentration and area under the curve increased proportionately with dosage, and that the half-life was ~2 h for all dosages."( Pharmacokinetics of 23-epi-26-deoxyactein in women after oral administration of a standardized extract of black cohosh.
Banuvar, S; Bolton, JL; Chen, SN; Fabricant, DS; Farnsworth, NR; Geller, SE; Hedayat, S; Krause, EC; Krock, KM; Liang, W; Nikolic, D; Pang, Y; Pauli, GF; Piersen, CE; Shulman, LP; Tao, Y; van Breemen, RB, 2010)		0.98

Bioavailability

ExcerptReferenceRelevance
" The results indicate high bioavailability of triterpene glycosides from C racemosa extract Ze 450."( In Vitro and In Situ Characterization of Triterpene Glycosides From Cimicifuga racemosa Extract.
Disch, L; Drewe, J; Forsch, K; Fricker, G; Siewert, B, 2017)		0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
triterpenoidAny terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (36.36)29.6817
2010's7 (63.64)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.62

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.62 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.62)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (9.09%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
metformin
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.		2.110guanidinesenvironmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic
midazolam
Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.		2.0610imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound		anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative
protopine
[no description available]		2.110dibenzazecine alkaloidplant metabolite
tyrosine
Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.		2.0810amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine		EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical
thiazoles
[no description available]		2.08101,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene
thiazolyl blue
thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.		2.0810organic bromide saltcolorimetric reagent;
dye
3-nitrotyrosine
3-nitrotyrosine: RN given refers to parent cpd without isomeric designation. 3-nitrotyrosine : A nitrotyrosine comprising tyrosine having a nitro group at the 3-position on the phenyl ring.		2.08102-nitrophenols;
C-nitro compound;
nitrotyrosine;
non-proteinogenic alpha-amino acid
lanosterol
[no description available]		2.031014alpha-methyl steroid;
3beta-sterol;
tetracyclic triterpenoid		bacterial metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite
gamma-sitosterol
clionasterol : A member of the class of phytosterols that is poriferast-5-ene carrying a beta-hydroxy substituent at position 3.		2.03103beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
phytosterols		marine metabolite;
plant metabolite
glycosides
[no description available]		2.9740
cytellin
cytellin: a phytosterol preparation of mainly B-sitosterol, that was marketed by Eli Lilly to lower cholesterol 1957 to 1982		2.0310
antimycin a
Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.		2.4920amidobenzoic acid
beta-escin
[no description available]		5.24111
actein
actein: a cyclolanostane from the Chinese drug Shoma; structure in first source		2.0610triterpenoidmetabolite
26-deoxyactein
26-deoxyactein: cyclolanostane from the Chinese drug Shoma; structure in first source		2.4220triterpenoidmetabolite
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight
The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.		02.110
Diabetes Mellitus, Adult-Onset
[description not available]		02.110
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.110
Insulin Sensitivity
[description not available]		02.110
Diabetes Mellitus, Type 2
A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.		02.110
Insulin Resistance
Diminished effectiveness of INSULIN in lowering blood sugar levels: requiring the use of 200 units or more of insulin per day to prevent HYPERGLYCEMIA or KETOSIS.		02.110
Menopause
The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age.		03.4411
Calcification, Pathologic
[description not available]		02.0810
Calcinosis
Pathologic deposition of calcium salts in tissues.		02.0810